panobinostat + docetaxel + prednisone

Panobinostat + docetaxel + prednisone is an experimental combination therapy evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). **Panobinostat** is a pan-histone deacetylase (HDAC) inhibitor that induces cell cycle arrest and apoptosis by modulating gene expression. **Docetaxel** is a taxane-class cytotoxic chemotherapeutic that inhibits microtubule depolymerization, causing cell-cycle arrest at the G2/M phase. **Prednisone** is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive properties, and also commonly paired with docetaxel in mCRPC to reduce some side effects and possibly enhance efficacy. This combination was tested in phase I trials to determine safety and early indications of activity in castration-resistant prostate cancer, showing some preliminary evidence of PSA reduction and feasibility for further study[1][3][6].

Brand names

Farydak (for panobinostat)